Subdermal Contraceptive Implants Market Size & Share, by Product (Etonogestrel Implant, Levonorgestrel Implant); Application (Hospital, Gynecology Clinics, Research Facilities, Women Healthcare Centers); Type (Biodegradable, Non-Biodegradable) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5300
  • Published Date: Oct 09, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Subdermal Contraceptive Implants Market size is poised to cross USD 3 Billion by the end of 2036, growing at a CAGR of 9% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of subdermal contraceptive implants was USD 1.05 Billion. The reason behind the growth is impelled by the rising count of unintended pregnancies. Subdermal contraceptive implants is an effective method to avoid unwanted pregnancies for women and couples, as it can stop pregnancies for three to five years. For instance, globally, there are more than 120 million unplanned pregnancies per year, or close to half of all pregnancies.

The rising governmental initiative to utilize contraceptive procedures are believed to fuel the market growth. For instance, the World Health Organization (WHO) is supporting nations to better their contraceptive policies and practices and also taking part in the development of new contraceptive methods.

Subdermal Contraceptive Implant Market
Get more information on this report: Request Free Sample PDF

Subdermal Contraceptive Implants Market: Growth Drivers and Challenges

Growth Drivers

  • Rising Awareness about Family Planning – As a result, the demand for subdermal contraceptive implants is expected to rise as they have a huge potential to help in family planning, and are one of the most practical, accessible, and increasingly accepted forms of family planning in the world. Globally, more than 60% percent of married women between the ages of 15 and 49 practice family planning.
  • Increasing Knowledge about Contraceptives- Educational interventions across the globe are helping to increase the knowledge of available contraceptive methods, which has led to an increase in the adoption of subdermal contraceptive implants as an acceptable means of contraception for adolescent girls and young women.


  • Side Effects of Subdermal Contraceptive Implants- There are a few side effects that some people experience after receiving implants which include menstrual irregularities, headaches, weight gain, acne, dizziness, mood swings, nausea, lower abdominal pain, hair loss, loss of libido, pain at the implant site, neuropathy, and follicular cysts.

Additionally, implanon (etonogestrel) a contraceptive used to prevent pregnancy can cause serious eye symptoms, serious heart symptoms, and severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination. Furthermore, it should not be used at the time of pregnancy as it can lead to a certain serious pregnancy issue (ectopic pregnancy).

  • Lack of Awareness in Developing Regions
  • Lack of Skilled Professionals to Insert and Remove these Implants

Subdermal Contraceptive Implants Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 1.06 Billion

Forecast Year Market Size (2036)

~ USD 3 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Subdermal Contraceptive Implants Segmentation

Product (Etonogestrel Implant, Levonorgestrel Implant)

The etonogestrel implant segment is estimated to hold 66% share of the global subdermal contraceptive implants market during the forecast period. Etonogestrel implant is a hormonal birth control method that comes in the form of a flexible plastic matchstick-sized rod. Additionally, the U.S. Food and Drug Administration has given the etonogestrel subdermal implant approval for contraception for up to three years as a highly effective contraceptive option for women. Moreover, the etonogestrel implant has a failure rate of less than 1%, making it more efficient than female sterilization.

Application (Hospital, Gynecology Clinics, Research Facilities, Women Healthcare Centers)

Subdermal contraceptive implants market from the hospital segment is set to garner a notable share shortly. Subdermal contraceptive implant procedure is usually performed within the hospital premises whereby the gynecologist places the implant in the non-dominant arm, typically, in the consultation room by using a local anesthetic. Besides this, sometimes there may be a need for specialized procedures, including hospital surgery if it gets difficult to remove the implant, or it cannot be found.

Type (Biodegradable, Non-Biodegradable)

Subdermal contraceptive implants market from the biodegradable segment is set to garner significant share by the year 2036. Levonorgestrel (LNG) biodegradable subcutaneous implants have emerged as the most promising long-term contraceptive methods as they release a contraceptive steroid for a predetermined amount of time before dissolving. Besides this, a subdermal biodegradable contraceptive implant is used to provide secure and reliable contraception, as it is a low-cost, biodegradable implant system in the form of a subdermal pellet, is extremely adaptable, and does not need to be surgically removed.

Our in-depth analysis of the global subdermal contraceptive implants market includes the following segments:


  • Etonogestrel Implant
  • Levonorgestrel Implant


  • Hospital
  • Gynecology Clinics
  • Research Facilities
  • Women Healthcare Centers


  • Biodegradable
  • Non-Biodegradable

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Subdermal Contraceptive Implants Industry- Regional Synopsis

North American Market Forecast

Subdermal contraceptive implants market in North America is predicted to account for the largest share of 55% by 2036 impelled by the availability of contraceptive implants. Nexplanon which resembles a matchstick in size and is a tiny, thin rod is the implant that is offered in the US. Besides this, Canada has now authorized the use of Nexplanon to give patients in the country an essential and long-overdue expansion of their options for contraception. For instance, Women in the US had access to over 50% of the contraceptive products available globally, as compared to approximately 34% for Canadian women.

APAC Market Statistics

The APAC subdermal contraceptive implants market is estimated to be the second largest, during the forecast timeframe led by rising government’s initiatives to improve access to contraceptive methods. The Indian government has made important strides towards enhancing sexual and reproductive health at the national, local, and rural levels by launching various initiatives such as Mission Parivar Vikas, which will greatly expand access to family planning and contraceptives. For instance, lately, India's adoption of the Sustainable Development Goals (SDG) indicator over 3 intends to ensure that everyone has access to sexual and reproductive health care services by 2030 by meeting three-fourths of family planning needs with contemporary contraceptive methods.

Research Nester
Subdermal Contraceptive Implant Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Subdermal Contraceptive Implants Market

    • Merck & Co., Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Shanghai Dahua Pharmaceutical Co., Ltd,
    • Bayer AG
    • Wyeth Pharmaceuticals
    • Baxter
    • Gerresheimer AG
    • Theramex
    • Contraline, Inc.
    •  Pfizer, Inc.
    • Novartis AG
    • Schott AG
    • Eli Lilly and Company
    • Sandoz International GmbH
    • Teva Pharmaceutical Industries Ltd.

In the News

  • Shanghai Dahua Pharmaceutical Co., Ltd, along with DKT WomanCare announced to reduce the price of, a two-rod contraceptive implant Levoplant that was recently approved to enhance women's reproductive health autonomy. Furthermore, it will now cost qualified buyers around USD 6 which will aid in increasing access to a high-quality contraceptive for those who need it the most and will make it easier for people who require access to quality contraception.
  • Contraline, Inc. announced to investment of over USD 7 million for the creation of the first injectable hydrogel-based implanted male contraceptives to create a long-acting, reversible male contraceptive that gives more individuals more choices for family planning and changes how people think about contraception.
  • Teva Pharmaceutical Industries Ltd. introduced a Generic Version of NuvaRing intended for use by women of reproductive age that combines estrogen and progestin to prevent conception. Furthermore, the product is an essential addition to Teva's generic product line which must be worn for three weeks.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5300
  • Published Date: Oct 09, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising count of unintended pregnancies and the rising governmental initiative to utilize contraceptive procedures are the major factors driving the growth of the market.

The market size of subdermal contraceptive implants is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2024-2036.

The major players in the market are Shanghai Dahua Pharmaceutical Co., Ltd, Bayer AG, Wyeth Pharmaceuticals, Baxter, Gerresheimer AG, Pfizer, Inc., Novartis AG, Schott AG, Eli Lilly and Company, and others.

The etonogestrel implant segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Subdermal Contraceptive Implants Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying